纯度
≥ 90 % as determined by SDS-PAGE.
内毒素
< 0.1 EU/μg of the protein by LAL method.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
描述
Recombinant human TNFSF13B/BAFF/CD257 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala134-Leu285) of human TNFSF13B/BAFF/CD257 (Accession #NP_006564.1) fused with a 6×His tag at the N-terminus.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
（1）未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周；
（2）干粉蛋白复溶浓度建议在0.1-0.5 mg/mL，不能低于0.1mg/mL，长期储存请添加保护剂（如0.1%BSA），并分装保存，避免反复冻融；
（3）液体蛋白的保存温度及效期请参考说明书，如对液体蛋白浓度有要求，请提前咨询销售或者技术支持。
生物活性
Measured by its binding ability in a functional ELISA.Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μg/mL (100 μL/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！
B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sj?gren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
